BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Baikonur launch pad damaged after Russian Soyuz launch to International Space Station - 2Want to read more in 2026? Here's how to revive your love of books
- 36 Famous Urban communities for Shopping on the planet
- 4Commonsense Ways to work on Your Funds with a Restricted Pay
- 5How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- Embrace the Outside: Exercises and Entertainment
- Germany records first wolf bite on human since repopulation
- Charity 'feels the pinch' of higher energy prices
- Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- South Carolina's measles outbreak reaches 434 cases
- Instructions to Floss Appropriately and Forestall Gum Sickness
- 'You're no longer my sister' - rows erupt as war divides Iranian families
- 10 Moves toward Start Your Own Effective Business
- 6 Web-based Staple Help You Can Trust
